BR112023017731A2 - Moduladores de sting (estimulador de genes de interferon) - Google Patents

Moduladores de sting (estimulador de genes de interferon)

Info

Publication number
BR112023017731A2
BR112023017731A2 BR112023017731A BR112023017731A BR112023017731A2 BR 112023017731 A2 BR112023017731 A2 BR 112023017731A2 BR 112023017731 A BR112023017731 A BR 112023017731A BR 112023017731 A BR112023017731 A BR 112023017731A BR 112023017731 A2 BR112023017731 A2 BR 112023017731A2
Authority
BR
Brazil
Prior art keywords
interferon gene
gene stimulator
sting modulators
compounds
sting
Prior art date
Application number
BR112023017731A
Other languages
English (en)
Inventor
Woo Huh Chan
Yuanjin Rui Eugene
Jianmin Sun
Satish Gajiwala Ketan
James Wythes Martin
Mehran Jalaie
Lloyd Patman Ryan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR112023017731A2 publication Critical patent/BR112023017731A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

moduladores de sting (estimulador de genes de interferon). a presente invenção refere-se a compostos da fórmula geral (i) e sais farmaceuticamente aceitáveis dos mesmos, processos para a preparação desses compostos, composições contendo esses compostos e aos usos dos mesmos como moduladores de sting (estimulador de genes de interferon).
BR112023017731A 2021-03-18 2022-03-15 Moduladores de sting (estimulador de genes de interferon) BR112023017731A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162640P 2021-03-18 2021-03-18
US202163165459P 2021-03-24 2021-03-24
PCT/IB2022/052300 WO2022195462A1 (en) 2021-03-18 2022-03-15 Modulators of sting (stimulator of interferon genes)

Publications (1)

Publication Number Publication Date
BR112023017731A2 true BR112023017731A2 (pt) 2023-10-03

Family

ID=80819922

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023017731A BR112023017731A2 (pt) 2021-03-18 2022-03-15 Moduladores de sting (estimulador de genes de interferon)

Country Status (15)

Country Link
US (1) US11964978B2 (pt)
EP (1) EP4308563A1 (pt)
JP (1) JP2024509982A (pt)
KR (1) KR20230146606A (pt)
AU (1) AU2022238001A1 (pt)
BR (1) BR112023017731A2 (pt)
CA (1) CA3213427A1 (pt)
CO (1) CO2023012198A2 (pt)
CR (1) CR20230413A (pt)
DO (1) DOP2023000194A (pt)
EC (1) ECSP23070418A (pt)
IL (1) IL306034A (pt)
TW (1) TWI829112B (pt)
UY (1) UY39676A (pt)
WO (1) WO2022195462A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222644A1 (en) 2022-05-18 2023-11-23 F. Hoffmann-La Roche Ag Pyrazole derivatives as sting agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
MY162737A (en) 2010-09-09 2017-07-14 Pfizer 4-1bb binding molecules
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20190031765A1 (en) 2016-01-25 2019-01-31 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
CN109563081A (zh) * 2016-04-07 2019-04-02 葛兰素史克知识产权开发有限公司 可用作蛋白调节剂的杂环酰胺类
CA3024482A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
JP7296954B2 (ja) * 2017-06-22 2023-06-23 キュラデブ・ファーマ・リミテッド ヒトｓｔｉｎｇの小分子調節因子
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
US11008344B2 (en) * 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
US20220168309A1 (en) * 2019-03-05 2022-06-02 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020232375A1 (en) * 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
KR20220070254A (ko) 2019-09-25 2022-05-30 화이자 인코포레이티드 Sting (인터페론 유전자의 자극인자)의 폴리헤테로시클릭 조정제

Also Published As

Publication number Publication date
IL306034A (en) 2023-11-01
ECSP23070418A (es) 2023-10-31
TWI829112B (zh) 2024-01-11
DOP2023000194A (es) 2023-11-30
CO2023012198A2 (es) 2023-11-30
JP2024509982A (ja) 2024-03-05
EP4308563A1 (en) 2024-01-24
TW202246262A (zh) 2022-12-01
US11964978B2 (en) 2024-04-23
AU2022238001A1 (en) 2023-09-14
KR20230146606A (ko) 2023-10-19
WO2022195462A1 (en) 2022-09-22
CA3213427A1 (en) 2022-09-22
US20220306641A1 (en) 2022-09-29
UY39676A (es) 2022-10-31
CR20230413A (es) 2023-10-13

Similar Documents

Publication Publication Date Title
ECSP20004580A (es) Moduladores de moléculas pequeñas de sting humana
CL2020002156A1 (es) Agentes de iarn para infección causada por el virus de la hepatitis b. (divisional solicitud 201900278).
BR112017005917A2 (pt) processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana
CL2018001484A1 (es) Dinucleotidas de purino ciclico como moduladores de estimulador de genes de interferon (sting).
BR112014022106A2 (pt) derivados macrocíclicos para o tratamento de doenças
BR112022005463A2 (pt) Moduladores poli-heterocíclicos de sting (estimulador de genes de interferon)
BR112018014278A2 (pt) processos para a preparação de ácido 2,5-furandicarboxílico e intermediários e derivados dos mesmos
BR112014031375A2 (pt) moduladores da série de reação complementar e usos dos mesmos
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112018011929A2 (pt) composto, composição farmacêutica, métodos para tratamento da infecção viral da hepatite c, de carcinoma basocelular, de ceratose actínica, da infecção viral de papiloma genital e da infecção viral de hepatite c, processo para preparação de um composto, e, uso de um composto
BR112018003343A2 (pt) compostos heteroarila como inibidores de irak e usos dos mesmos
BR112017004741A2 (pt) compostos e composições como inibidores da raf quinase
BR112012027062B8 (pt) composto, processo para a preparação de um composto e usos do mesmo
BR112018003812A2 (pt) compostos de heteroarila como inibidores de irak e usos dos mesmos
BR112021024948A2 (pt) Moduladores de próxima geração de estimulador de genes de interferon (sting)
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
BR112021000796A2 (pt) Processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina e (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol
BR112018070363A2 (pt) derivados de tetraidroisoquinolina
MX2016013151A (es) Nuevos derivados quinona de cannabidiol.